Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study

BACKGROUND: The tyrosine kinase inhibitor pazopanib is used for treatment of sarcoma. Recent studies have suggested that the use of pazopanib may lead to the development of pneumothorax, an unexpected adverse effect in patients with sarcoma metastatic to the chest. METHODS: We conducted a retrospect...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Cancer
Главные авторы: Sabath, Bruce, Muhammad, Hasan A, Balagani, Amulya, Ost, David E, Vakil, Erik, Ahmed, Tahreem, Vial, Macarena R, Grosu, Horiana B
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2018
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167904/
https://ncbi.nlm.nih.gov/pubmed/30285733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4858-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы